• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar

McCarter & English Logo

  • People
  • Services
  • Insights
  • Our Firm
    • Leadership Team
    • Social Justice
    • Diversity & Inclusion
    • Pro Bono
    • Client Service Values
  • Join Us
    • Lawyers
    • Summer Associates
    • Patent Professionals
    • Professional Staff
    • Job Openings
  • Locations
    • Boston
    • Philadelphia
    • East Brunswick
    • Stamford
    • Hartford
    • Trenton
    • Newark
    • Washington, DC
    • New York
    • Wilmington
  • Share

Share

Browse Alphabetically:

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
  • All
Bankruptcy, Restructuring & Litigation
Blockchain, Smart Contracts & Digital Currencies
Business Litigation
Cannabis
Coronavirus Resource Center
Corporate
Crisis Management
Cybersecurity & Data Privacy
Delaware Corporate, LLC & Partnership Law
Design, Fashion & Luxury
E-Discovery & Records Management
Energy & Utilities
Environment & Energy
Financial Institutions
Government Affairs
Government Contracts & Global Trade
Government Investigations & White Collar Defense
Healthcare
Immigration
Impact Investing
Insurance Recovery, Litigation & Counseling
Intellectual Property
Labor & Employment Law
Life Sciences
Manufacturing
Products Liability, Mass Torts & Consumer Class Actions
Proptech
Public Finance 
Real Estate
Renewable Energy
Sports & Entertainment
Tax & Employee Benefits 
Technology Transactions
Transportation, Logistics & Supply Chain Management
Trusts, Estates & Private Clients 
Venture Capital & Emerging Growth Companies
  • Broadcasts
  • Events
  • News
  • Publications
  • View All Insights
Search By:
Insights News Headline Stack
Main image for Chondrial Therapeutics and Zafgen Announce Definitive Merger Agreement
News|Press

Chondrial Therapeutics and Zafgen Announce Definitive Merger Agreement

12.18.2019

A multidisciplinary team of McCarter lawyers advised Chondrial Therapeutics, Inc., on its definitive merger agreement with Zafgen, Inc. (Nasdaq: ZFGN) under which Chondrial will acquire Zafgen in a reverse merger wherein the stockholders of Chondrial will become the majority owners of Zafgen’s outstanding common stock. The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under the name Larimar Therapeutics, Inc. 

Chondrial Therapeutics is a clinical-stage biotechnology company focused on the treatment of complex rare diseases. Zafgen is a biopharmaceutical company that has leveraged its proprietary biology platform to pioneer the study of common and rare metabolic disorders.

McCarter’s team was led by Philip Amoa and Peter Campitiello, and included Dan Kelly, Pat Harrity, Debra Levin, Jill Mello, Keith Toms, Joel Horowitz, Sheri Pastor, Pam Moore, and Rich Hernandez.

Additional details are available in the press release.

sidebar

pdfemail

Related People

Sherilyn Pastor
Richard Hernandez
Pamela J. Moore
Philip D. Amoa
Peter Campitiello
Daniel J. Kelly
Patrick Harrity
Debra E. Levin
Jill Ann Mello, PhD
Keith Toms
Joel E. Horowitz

Related Services

Intellectual Property
Corporate
Employee Benefits & Executive Compensation
Insurance Recovery, Litigation & Counseling
Labor & Employment Law
Antitrust
Subscribe to our Insights
McCarter & English, LLP
Copyright © 2021 McCarter & English, LLP. All Rights Reserved.
  • Login
  • Attorney Advertising
  • Privacy
  • Awards Methodology
  • Contact
  • Subscribe
  • Sitemap

The McCarter & English, LLP website is for informational purposes only. We do not provide legal advice on this website. We can provide legal advice only to our clients in specific inquiries that they address to us. If you are interested in becoming a client, please contact us, but do not send any information about your specific legal question. We cannot serve as your lawyers until we establish an attorney-client relationship, which can occur only after we follow procedures within our firm and after we agree to the terms of the representation.

Accept Cancel